Latest Breaking News On - Bruno wohlschlegel - Page 1 : comparemela.com

APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed

APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Bruno wohlschlegelThomas milzThomas zimmermannSven paulyMonheim rheinGroup novartisCondensed group statement of financial positionCondensed group statement of cashCondensed group statement of incomeSingle pillManagement boardConference callGroup statementFinancial positionCash flowsSingle pills

EQS-News: APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast

EQS-News: APONTIS PHARMA AG / Key word(s): Change in Forecast/Alliance APONTIS PHARMA enters five-year distribution and mark.

Novartis pharma gmbBruno wohlschlegelMonheim rheinSven paulyNovartis pharma gmbhChief executive officerSingle pillSingle pills

APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma me

EQS-News: APONTIS PHARMA AG / Key word(s): Change in Forecast/AllianceAPONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast 05.04.2024 / 10:17 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA enter.

Bruno wohlschlegelSven paulyMonheim rheinNovartis pharma gmbDistribution servicesNovartis pharma gmbhChief executive officerSingle pillSingle pillsCorporate newsRegulatory announcements

APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast

EQS-News: APONTIS PHARMA AG / Key word: Change in Forecast/Alliance APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications.

Sven paulyMonheim rheinNovartis pharma gmbBruno wohlschlegelNovartis pharma gmbhChief executive officerSingle pillSingle pills

APONTIS PHARMA expects profitable growth again in 2024

EQS-News: APONTIS PHARMA AG / Key word: Annual Results/Annual Report APONTIS PHARMA expects profitable growth again in 2024 28.03.2024 / 07:30 CET/CEST The issuer is.

Thomas zimmermannSven paulyMonheim rheinThomas milzBruno wohlschlegelCondensed group income statementCondensed group statement of cashSingle pillChief executive officerConsolidated statementGroup statementSingle pills